We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
- Authors
Sobolewska-Włodarczyk, Aleksandra; Włodarczyk, Marcin; Storr, Martin; Fichna, Jakub
- Abstract
Diarrhea-predominant irritable bowel syndrome (IBS-D) belongs to the group of functional gastrointestinal disorders and is characterized by abdominal pain in conjunction with diarrhea. The incidence of IBS-D is currently increasing, leading to a heavy economic burden for patients and health care systems worldwide. Recent studies suggest eluxadoline as an attractive new tool for the treatment of patients with IBS-D. Eluxadoline is an orally active μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, with powerful antidiarrheal and analgesic activity. Eluxadoline is believed to act locally in the enteric nervous system, and has no adverse effects in the central nervous system. In this review, we discuss the most recent findings on the mechanism of action of eluxadoline and the results of the clinical trials in patients with IBS-D. We also discuss possible side effects and analyze the potential of eluxadoline to be used in the treatment of IBS-D.
- Subjects
IRRITABLE colon treatment; OPIOID receptors; DIARRHEA; ABDOMINAL pain; ENTERIC nervous system; ANTIDIARRHEALS
- Publication
Therapeutics & Clinical Risk Management, 2016, Vol 12, p771
- ISSN
1176-6336
- Publication type
journal article
- DOI
10.2147/TCRM.S83722